webinar register page

Webinar banner
Advances in Lymphatic Mapping and Sentinel Lymph Node Biopsy in Breast Cancer Care
Join Dr. Vincent Reid and Dr. Linda Han for a free (NON-accredited) webinar on LYMPHOSEEK® presented by Cardinal Health Nuclear & Precision Health Solutions. You will learn the results of a patient case study, and have the opportunity to ask our presenter questions about his own clinical experience with LYMPHOSEEK®.

Indication and Usage
LYMPHOSEEK® is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:
·Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adults and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management.
·Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Abbreviated Important Safety Information
In clinical trials with LYMPHOSEEK®, no serious hypersensitivity reactions were reported, however LYMPHOSEEK® may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs). Prior to the administration of LYMPHOSEEK®, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of LYMPHOSEEK® administration, and patients observed for signs or symptoms of hypersensitivity following injection.Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (less than 1%).

Oct 6, 2022 12:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading